Global Single-Use Bioreactors Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Single-Use Bioreactors Market Size

• The global single-use bioreactors market size was valued at USD 7.79 billion in 2024 and is expected to reach USD 25.65 billion by 2032, at a CAGR of 16.05% during the forecast period
• The market growth is largely fueled by the increasing demand for biologics, the need for flexible and scalable manufacturing solutions, and the advantages of single-use technologies over traditional stainless-steel systems, enabling faster and more cost-effective production in biopharmaceutical settings
• Furthermore, rising adoption in North America, along with rapid growth in emerging markets such as Asia-Pacific and Latin America, is driving the uptake of single-use bioreactors, as pharmaceutical companies and contract manufacturing organizations seek efficient, scalable, and user-friendly biomanufacturing solutions

Single-Use Bioreactors Market Analysis

• Single-use bioreactors, providing disposable and scalable biomanufacturing solutions, are increasingly critical in modern biopharmaceutical production for vaccines, monoclonal antibodies, and other biologics due to their flexibility, reduced contamination risk, and faster turnaround times compared to traditional stainless-steel systems
• The rising demand for single-use bioreactors is primarily driven by the increasing production of biologics, growing adoption of flexible manufacturing platforms, and the need for cost-effective and efficient production processes in both large pharmaceutical companies and contract manufacturing organizations (CMOs)
• North America dominated the single-use bioreactors market with the largest revenue share of 39% in 2024, supported by a well-established biopharmaceutical sector, significant investments in biomanufacturing infrastructure, and the presence of key industry players such as Sartorius AG, Thermo Fisher Scientific, and Merck KGaA, with the U.S. witnessing substantial adoption in vaccine and therapeutic protein production
• Asia-Pacific is expected to be the fastest-growing region in the single-use bioreactors market during the forecast period, due to increasing biopharmaceutical manufacturing capabilities, supportive government initiatives, and rising investments from both local and international companies
• Stirred Tank Single-use Bioreactors segment dominated the market with a share of 46.8% in 2024, driven by their proven performance, ease of scale-up, and compatibility with a wide range of cell culture processes

Report Scope and Single-Use Bioreactors Market Segmentation      

Single-Use Bioreactors Market Trends

Shift Towards Advanced Single-Use and Modular Systems

• A Key and accelerating trend in the global single-use bioreactors market is the development of advanced disposable systems with modular designs that allow easy scale-up and integration with automated biomanufacturing processes. This evolution is enhancing operational efficiency and reducing contamination risks
  • For Instance, The Xcellerex XDR-50 single-use bioreactor integrates modular sensors and automated control systems, allowing seamless adaptation for different cell culture processes and rapid production scaling
• Advanced single-use systems are incorporating real-time monitoring, automated feeding, and predictive process controls, enabling manufacturers to optimize yields and improve process consistency across batches
• The adoption of modular and standardized components facilitates compatibility with upstream and downstream processing, providing flexible solutions for diverse biopharmaceutical production needs
• This trend towards more intelligent, scalable, and adaptable single-use bioreactors is redefining manufacturing practices in biologics production. Consequently, companies such as Sartorius AG are developing next-generation bioreactors with fully integrated sensors, automated control, and disposable components
• The demand for advanced single-use bioreactors is growing rapidly across both large-scale and small-scale production facilities, as manufacturers increasingly prioritize flexibility, efficiency, and process control

Single-Use Bioreactors Market Dynamics

Driver

Biologics Production and Need for Flexible Manufacturing

• The increasing production of monoclonal antibodies, vaccines, and other biologics, coupled with the need for flexible and cost-effective manufacturing platforms, is a significant driver for single-use bioreactor adoption
  • For instance, In March 2024, Thermo Fisher Scientific expanded its HyPerforma single-use bioreactor line to support high-density cell culture for monoclonal antibody production, enhancing manufacturing flexibility
• As the demand for biologics grows globally, single-use bioreactors provide advantages such as reduced cleaning requirements, faster batch turnaround, and minimized cross-contamination, offering a compelling solution over traditional stainless-steel systems
• Furthermore, increasing use by contract manufacturing organizations (CMOs) and biotech startups is driving adoption, as these organizations seek scalable and modular production solutions to meet variable production demands
• The ease of implementing single-use bioreactors into existing facilities, combined with integration with automated and digital manufacturing platforms, is propelling market growth across diverse biopharmaceutical applications

Restraint/Challenge

High Costs and Regulatory Compliance Complexity

• The relatively high initial investment required for advanced single-use bioreactors, along with regulatory and validation requirements, poses a significant challenge to wider adoption, especially for small-scale manufacturers
  • For instance, High upfront costs for disposable bioreactor systems with integrated sensors and control modules can deter smaller biotech firms from adopting the latest technologies
• Compliance with stringent cGMP regulations and ensuring proper validation and documentation for single-use systems adds complexity, particularly in multi-product facilities
• In addition, concerns over material compatibility, leachables, and extractables from disposable components require rigorous testing and quality assurance, further increasing operational burden
• While the benefits of flexibility and faster turnaround are clear, overcoming cost barriers and addressing regulatory complexities through standardized protocols, training, and cost-effective solutions will be critical for sustained market growth

Single-Use Bioreactors Market Scope

The market is segmented on the basis of product, type, type of molecule, cell type, application, and end user.

• By Product

On the basis of product, the single-use bioreactors market is segmented into single-use bioreactor systems, single-use media bags, and single-use filtration assemblies. The single-use bioreactor systems segment dominated the market with the largest revenue share of 52.4% in 2024, driven by their ability to provide fully integrated, scalable, and flexible biomanufacturing solutions. Companies prefer these systems for large-scale production of monoclonal antibodies, vaccines, and other biologics due to reduced cleaning requirements and minimized contamination risks. The segment benefits from continuous innovations such as integrated sensors, automated control modules, and modular designs that improve process efficiency and reproducibility. The high reliability, compatibility with upstream and downstream processes, and ease of scale-up further strengthen its dominance. Demand is particularly strong in contract manufacturing organizations (CMOs) that require flexibility for multi-product facilities.

The single-use filtration assemblies segment is anticipated to witness the fastest growth at a CAGR of 23.8% from 2025 to 2032, fueled by increasing use in downstream processing for virus removal, protein clarification, and sterile filtration. Its single-use nature reduces contamination, labor, and cleaning costs. Expanding biologics production and regulatory emphasis on product purity are key growth drivers. Increasing adoption in CMOs and research facilities seeking efficient filtration solutions supports market expansion. Innovations in filtration membranes and disposable designs further enhance performance and reliability. The growing focus on speed-to-market and cost-efficiency strengthens this segment’s growth potential.

• By Type

On the basis of type, the single-use bioreactors market is segmented into stirred tank single-use bioreactors, bubble column single-use bioreactors, and wave-induced single-use bioreactors. The stirred tank single-use bioreactors segment dominated the market with the largest share of 46.8% in 2024 due to its proven performance in large-scale biomanufacturing, high oxygen transfer efficiency, and compatibility with mammalian cell cultures. Companies favor stirred tank designs for monoclonal antibody and vaccine production as they allow precise control over temperature, pH, and dissolved oxygen. Their robust design enables seamless scale-up from lab to commercial production while maintaining reproducibility. Integration with automation, process analytical technology (PAT), and digital control systems strengthens adoption. Flexibility for high-density cultures and modular configurations supports its leadership.

The wave-induced single-use bioreactors segment is expected to witness the fastest CAGR of 25.1% during 2025–2032, driven by suitability for smaller batch sizes, delicate cells such as stem cells or gene-modified cells, and ease of use in R&D. Its low shear environment ensures high cell viability and efficient growth. The disposable design reduces cleaning and cross-contamination risks. Growing demand in cell therapy, regenerative medicine, and clinical trials enhances adoption. Flexibility and portability make it ideal for multi-product facilities and pilot-scale production. Continuous product innovation and compatibility with automated monitoring strengthen growth.

• By Type of Molecule

On the basis of type of molecule, the single-use bioreactors market is segmented into monoclonal antibodies (MAbs), vaccines, stem cells, gene-modified cells, and other molecules. The monoclonal antibodies segment dominated the market with a revenue share of 44.7% in 2024, supported by high demand in oncology, autoimmune, and infectious diseases. Single-use bioreactors provide scalability, process control, and contamination-free production. Ongoing R&D, regulatory approvals, and adoption by commercial facilities strengthen this segment. Compatibility with high-density cell cultures improves yield and reproducibility. Advantages such as reduced downtime and faster batch turnover support leadership.

The stem cells segment is anticipated to witness the fastest growth rate of 26.4% during 2025–2032, fueled by regenerative medicine applications and investments in cell-based therapies. Single-use bioreactors offer controlled environments for delicate stem cell cultures. Scalability and disposable components reduce contamination risk. Growing clinical trials and commercialization opportunities accelerate adoption. Advanced monitoring systems enable process optimization. Emerging biotech companies increasingly prefer single-use systems for stem cell production.

• By Cell Type

On the basis of cell type, the single-use bioreactors market is segmented into mammalian cells, bacteria cells, yeast cells, and other cells. The mammalian cells segment dominated the market with a share of 50.5% in 2024, due to its use in monoclonal antibodies, vaccines, and recombinant proteins. Single-use bioreactors provide precise environmental control and high cell viability. Compatibility with high-density cultures supports large-scale production. Integration with digital and automated systems strengthens process reproducibility. Ease of scale-up from R&D to commercial production ensures flexibility. The segment is widely adopted across pharmaceutical and CMO facilities.

The bacteria cells segment is expected to witness the fastest CAGR of 24.7% from 2025 to 2032, driven by recombinant protein, enzyme, and industrial biologics production. Disposable bioreactors simplify bacterial culture handling and reduce contamination. Rapid growth rates of bacteria accelerate productivity. Regulatory focus on quality and safety drives adoption. Cost-effectiveness and flexibility for small-batch production strengthen growth. Innovative designs for monitoring and control enhance segment potential.

• By Application

On the basis of application, the single-use bioreactors market is segmented into research and development, process development, and bioproduction. The bioproduction segment dominated the market with the largest share of 55.2% in 2024, due to increasing commercialization of biologics and the need for efficient, contamination-free production. Single-use bioreactors reduce downtime and cleaning requirements. Multi-product facilities benefit from flexibility and scalability. Adoption by pharmaceutical companies and CMOs drives market leadership. Integration with automation and monitoring ensures consistent output. Rising demand for monoclonal antibodies and vaccines further supports growth.

The research and development segment is expected to witness the fastest CAGR of 25.6% during 2025–2032, driven by disposable, flexible systems for early-stage process optimization and cell line development. Ease of setup and low contamination risk enhance adoption. Growing preclinical studies and pilot-scale experiments support demand. Compatibility with automated systems improves efficiency. Flexibility for different cell types and molecules accelerates growth. Biotech startups increasingly rely on single-use R&D solutions.

• By End User

On the basis of end user, the single-use bioreactors market is segmented into pharmaceutical and biopharmaceutical companies, academic and research institutes, and CROs and CMOs. The pharmaceutical and biopharmaceutical companies segment dominated the market with a share of 49.8% in 2024, supported by large-scale biologics production and ongoing investments in single-use technologies. High demand for therapeutic proteins, vaccines, and monoclonal antibodies drives adoption. The segment benefits from scalability, reduced downtime, and contamination-free processes. Integration with automated platforms ensures consistent production. Multi-site manufacturing operations prefer single-use systems. Leadership is reinforced by established infrastructure and regulatory compliance.

The CROs and CMOs segment is anticipated to witness the fastest growth at a CAGR of 26.2% from 2025 to 2032, fueled by outsourcing of biopharmaceutical production and demand for flexible, modular solutions. Multi-product facilities benefit from disposable systems. Growing biotech startups rely on CMOs for production scalability. Reduced cleaning and faster batch turnover support efficiency. Advanced monitoring and control improve process consistency. Rising global outsourcing trends strengthen growth prospects.

Single-Use Bioreactors Market Regional Analysis

• North America dominated the single-use bioreactors market with the largest revenue share of 39% in 2024, supported by a well-established biopharmaceutical sector, significant investments in biomanufacturing infrastructure, and the presence of key industry players
• Companies in the region prioritize flexibility, efficiency, and contamination-free production, making single-use bioreactors a preferred choice for both commercial-scale manufacturing and contract manufacturing organizations (CMOs)
• This widespread adoption is further supported by high R&D expenditure, a strong presence of key industry players such as Thermo Fisher Scientific, Sartorius AG, and Merck KGaA, and the growing demand for monoclonal antibodies, vaccines, and other biologics

U.S. Single-Use Bioreactors Market Insight

The U.S. single-use bioreactors market captured the largest revenue share of 42% in 2024 within North America, driven by the country’s advanced biopharmaceutical industry and high adoption of flexible manufacturing technologies. Manufacturers increasingly prioritize disposable systems to reduce contamination risk and improve production efficiency. The growing demand for monoclonal antibodies, vaccines, and gene therapies is further propelling market expansion. Adoption is supported by established CMOs and large pharmaceutical companies investing in modular and automated single-use bioreactor systems. Moreover, U.S. government initiatives promoting biologics manufacturing and R&D activities are contributing significantly to market growth. The country’s robust infrastructure, skilled workforce, and regulatory support strengthen the dominance of single-use systems in commercial and clinical production.

Europe Single-Use Bioreactors Market Insight

The Europe single-use bioreactors market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing biologics production and stringent regulatory compliance requirements. Countries such as Germany, France, and Switzerland are investing heavily in single-use manufacturing solutions to reduce costs, improve efficiency, and comply with cGMP standards. The adoption is fueled by rising demand for vaccines, monoclonal antibodies, and other therapeutic proteins. European companies are increasingly integrating single-use bioreactors with automated monitoring and control systems for process optimization. The market is witnessing growth across research, process development, and commercial production facilities. In addition, environmental concerns and the preference for disposable systems over stainless-steel setups are further encouraging adoption.

U.K. Single-Use Bioreactors Market Insight

The U.K. single-use bioreactors market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the country’s focus on advanced biologics manufacturing and R&D. Adoption is fueled by increasing investments in modular and disposable biomanufacturing platforms by pharmaceutical and biotech companies. The market is supported by strong regulatory frameworks, robust research infrastructure, and rising contract manufacturing activities. The use of single-use systems reduces downtime, contamination risk, and validation requirements, appealing to both commercial and academic facilities. Growing government initiatives supporting innovation in biopharmaceutical production further stimulate market growth. The increasing number of cell and gene therapy projects enhances demand for scalable single-use bioreactors.

Germany Single-Use Bioreactors Market Insight

The Germany single-use bioreactors market is expected to expand at a considerable CAGR during the forecast period, fueled by the country’s strong biopharmaceutical sector and emphasis on innovation and efficiency. German manufacturers increasingly adopt single-use systems to optimize production of monoclonal antibodies, vaccines, and recombinant proteins. Integration with automated monitoring and control platforms allows enhanced process consistency and reproducibility. Environmental sustainability and reduced cleaning requirements make disposable bioreactors preferable over traditional stainless-steel systems. Rising investments in biomanufacturing infrastructure and skilled workforce availability further support market growth. Adoption spans commercial production, CMOs, and research facilities across the country.

Asia-Pacific Single-Use Bioreactors Market Insight

The Asia-Pacific single-use bioreactors market is poised to grow at the fastest CAGR of 25% during the forecast period of 2025 to 2032, driven by increasing biologics production, growing contract manufacturing activities, and rising R&D initiatives in countries such as China, India, and Japan. The region’s expanding biopharmaceutical infrastructure, coupled with government support for healthcare innovation, is fostering adoption of disposable systems. Affordability and accessibility of single-use technologies are improving due to regional manufacturing capabilities. Growing demand for vaccines, monoclonal antibodies, and cell therapies in emerging economies is accelerating market growth. The adoption of automated and modular systems enhances process efficiency and reduces contamination risk, attracting pharmaceutical companies and CMOs.

Japan Single-Use Bioreactors Market Insight

The Japan single-use bioreactors market is gaining momentum due to the country’s advanced biotechnology sector, focus on precision manufacturing, and demand for innovative biologics production. The market growth is supported by increasing adoption of automated, modular, and disposable systems in both commercial and clinical production. Integration with digital monitoring and control systems allows manufacturers to optimize yields and ensure reproducibility. The rising demand for vaccines, regenerative therapies, and monoclonal antibodies drives further adoption. Government initiatives promoting healthcare innovation and R&D investments strengthen market potential. Japan’s focus on high-quality, contamination-free production makes single-use bioreactors increasingly preferred over traditional systems.

India Single-Use Bioreactors Market Insight

The India single-use bioreactors market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the country’s expanding biopharmaceutical manufacturing base, rapid urbanization, and growing R&D investments. The adoption of disposable systems is driven by increasing production of vaccines, biosimilars, and therapeutic proteins. The government’s push towards biotechnology innovation and “Make in India” initiatives further encourage adoption of advanced single-use technologies. Affordable and locally manufactured single-use bioreactors are expanding accessibility to small and mid-sized pharmaceutical companies. Growing contract manufacturing and clinical production activities accelerate market growth. India’s emerging biotech ecosystem supports continued expansion of single-use bioreactor applications across research, process development, and commercial production.

Single-Use Bioreactors Market Share

The single-use bioreactors industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific, Inc. (U.S.)
• ABEC (U.S.)
• Applitech Biological Technology Co., Ltd. (China)
• Cytiva (U.S.)
• Sartorius S.A. (France)
• WuXi Biologics (China)
• Eppendorf SE (Germany)
• TECNIC (Spain)
• Getinge (Sweden)
• Lonza (Switzerland)
• GE Healthcare (U.S.)
• Bioengineering AG (Switzerland)
• Finesse Solutions, Inc. (U.S.)
• Pall Corporation (U.S.)
• Cellca GmbH (Germany)
• B. Braun SE (Germany)
• Antylia Scientific (U.S.)

What are the Recent Developments in Global Single-Use Bioreactors Market?

• In April 2025, Thermo Fisher Scientific Launched the 5L DynaDrive Single-Use Bioreactor. Thermo Fisher Scientific introduced the 5L DynaDrive Single-Use Bioreactor, a bench-scale system designed to accelerate process development and bring therapies to market faster. This innovative bioreactor aims to simplify and enhance the efficiency of bioprocessing workflows
• In April 2025, AGC Inc. Added 5,000 L Thermo Fisher Vessels at Yokohama, Japan Facility. AGC Inc., a contract development and manufacturing organization (CDMO), expanded its capabilities by introducing two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors at its Yokohama facility. This strategic move positions the site as one of the most advanced in Japan for large-scale mammalian-based biologics production, with GMP operations commencing in 2027.
• In March 2025, ABEC Unveiled Breakthrough Single-Use Bioreactor Technology for Cell Therapy Manufacturing. ABEC introduced a pioneering single-use bioreactor system designed to enhance the scalability and efficiency of cell therapy production processes. This advancement aims to meet the growing demand for personalized medicine and complex biologics, offering improved performance and reduced risk of contamination in cell therapy manufacturing
• In March 2025, Cytiva Broadened Xcellerex X-Platform to Include 500L and 2,000L Bioreactors. Cytiva expanded its Xcellerex X-Platform by introducing 500L and 2,000L single-use bioreactors, designed to address the challenges of large-scale biologics production. These bioreactors combine reliability, scalability, and flexibility, aiming to streamline the manufacturing process for complex biologics
• In September 2023, Getinge Launched Single-Use Bioreactor for Clinical Cell and Gene Therapies. Getinge introduced the AppliFlex ST GMP, a cutting-edge single-use bioreactor system designed to bridge the gap between research and clinical production in cell and gene therapy, as well as mRNA production. This launch empowers researchers with a turn-key solution to advance clinical application

SKU-34964